5 Tips for Success in Chinese Pharma
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Address: Guilinyang Develops Area, Haikou, Hainan province, P.R.China 571127
Tel: +86 898 6571 8261
Hainan Yishun Pharmaceutical Co,. Ltd is a modern large pharmaceutical enterprise, which is established in Jun 6, 2003, with a registered capital of 50 million RMB (about 7.8 million dollars) and fixed asserts of 100 million RMB (about 15.7 million dollars). Company is located in Guilinyang Develops Area, Haikou, Hainan province, P.R.China. The plant area is more than 12,000 square meters, with a staff of more than 200. There are several production lines: powder for injection, new-type solid dosage form, APIs, small capacity injection and lyophilized powder for injection. All the production lines, staff and facility are organized and built strictly by GMP standard, and pass through and obtain new version SFDA-GMP certificate. On the aspect of quality control and quality assurance, we start with a high standard to build new plants, to introduce advanced production equipments, to be equipped with state-level drug quality testing instruments. All the efforts we make are to establish a comprehensive quality control and quality assurance system to supervise every link of drug production, sale and recall to ensure product quality. The whole process is in strict accordance with GMP requirements to implement and manage.
For overseas market, we will focus on promoting products of lyophilized powder for injection and sterile powder for injection. There is a products catalog available for international registration and sale. The overseas target markets of the company are Southeast Asia, Africa and Latin America. The company is looking for long-term partners and agents to create business opportunities and to achieve a win-win situation.
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017;…
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit…
Adam Dunnett, secretary general of the European Union Chamber of Commerce in China (European Chamber) outlines the organization’s three key roles of advocacy, providing business intelligence and strengthening the European…
Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon…
Davide Dalle Fusine, general manager for Chiesi China, shares the key milestones for the company in the past five years, their leadership position in neonatology and strength respiratory franchise in…
See our Cookie Privacy Policy Here